Infantile hemangioma (IH) is one of the common benign tumors in infants and children, with an incidence of 1-10%. there are significant gender differences in the incidence of IH, with females outnumbering males by a ratio of about 3-5:1. the incidence varies slightly by race. The prevalence is as high as 5-10% in Caucasian populations and about 2.8% in infants and children of African descent. In drought-stricken infants, low body mass at birth is a risk factor for the development of IH, and the risk of developing IH can increase by 40% for every 500 g reduction in body mass.IH has a unique life cycle, which is basically divided into two phases, including a proliferative and a receding phase. It is detected by parents 2-4 weeks after birth, grows decisively between 4 weeks and 6 months, and begins to recede after 6 months. 80% of patients have a basic or complete regression by the age of 7-12 years. The etiology, pathology, growth mechanism and biology of hemangiomas are not fully understood to date. Although IH is a benign vascular lesion and most of them are self-limiting, there are many types of IH, and a multicenter bulk study in the United States found complications in about 24% of patients with specific sites and specific types of hemangiomas, which have been a challenge for clinical treatment. The successful application of propranolol for the treatment of hemangioma has led to a new breakthrough in the treatment of hemangioma, and it is gradually becoming a first-line drug for the treatment of hemangioma.